Skip to content

A study of molecular markers and risk stratification in Indian women with endometrial cancer.

A study of molecular markers and risk stratification in Indian women with endometrial cancer: An Ambispective study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/077413
Enrollment
150
Registered
2024-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C541- Malignant neoplasm of endometrium

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

AIIMS Rishikesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histological diagnosis of endometrial cancer. 2. Execution of hysterectomy (with or without salpingo-oophorectomy) with or without nodal dissection 3. All stages of endometrial carcinoma (I-IV)

Exclusion criteria

Exclusion criteria: 1. Consent withdrawal 2. Patients with poor-quality slides/blocks (making pathological assessment difficult) 3. Poor quality of DNA obtained

Design outcomes

Primary

MeasureTime frame
1. Number and percentage of cases with positive molecular markers (PoleMutated, MLH1, MSH2, MSH6, and PMS2, p53 abnormal). 2. Risk stratification based on surgico-pathological risk groups and molecular findings (low, intermediate, high-intermediate, high, and advanced/metastatic) ESMO-ESGO-ESTRO 2016 and ESGO-ESTRO-ESP 2020 risk group classification. 3. The number of cases that were upstaged or downstaged as per FIGO staging 2009 and 2023.Timepoint: Baseline, 1 year, 3 year, 5 years

Secondary

MeasureTime frame
1. Number and percentage of cases who were multiple classifiers. 2. Involvement of myometrium, surgical margins, bilateral adnexa, cervical stroma, lymphovascular invasion, pelvic or para-aortic lymph nodes vis-a-vis molecular markers. 3. A number of women received adjuvant therapies in the form of brachytherapy, external beam radiotherapy, or chemoradiation. 4. Kaplan Meier curve for survival statistics. 5. L1CAM, ER, PR, and HER2-neu expression, CTNNB1, PTEN, E-cadherin, ARID1A mutations.Timepoint: 2 years

Countries

India

Contacts

Public ContactKavita Khoiwal

AIIMS Rishikesh

jaya_sunil@yahoo.com9690396908

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026